Portions of this work underlie a provisional patent application (PCT/CA2013/000920
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Products to support your goals Find products* you may need along your journey, from snacks and supplements to hydration, digestive support and more
Since thirst signals sometimes decrease during Retatrutide treatment, you can become mildly dehydrated without the usual warning signs
Doctors adjust dosing all the time based on individual patient needs
Retatrutide targets three different receptors: GLP-1 (helps regulate appetite and blood sugar) GIP (supports insulin response) Glucagon (affects energy use and fat metabolism) By targeting all three, the medication delays how fast your stomach digests food, lowers your appetite, and ultimately reduces how much food you eat